Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F22%3A10440017" target="_blank" >RIV/00064165:_____/22:10440017 - isvavai.cz</a>
Alternative codes found
RIV/00064173:_____/22:43923008 RIV/00064203:_____/22:10440017 RIV/00216208:11110/22:10440017 RIV/00216208:11120/22:43923008 RIV/00216208:11130/22:10440017
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=B5MWllWXjt" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=B5MWllWXjt</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.trecan.2022.01.010" target="_blank" >10.1016/j.trecan.2022.01.010</a>
Alternative languages
Result language
angličtina
Original language name
Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents
Original language description
At odds with other solid tumors, epithelial ovarian cancer (EOC) is poorly sensitive to immune checkpoint inhibitors (ICIs), largely reflecting active immunosuppression despite CD8(+) T cell infiltration at baseline. Accumulating evidence indicates that both conventional chemotherapeutics and targeted anticancer agents commonly used in the clinical management of EOC not only mediate a cytostatic and cytotoxic activity against malignant cells, but also drive therapeutically relevant immunostimulatory or immunosuppressive effects. Here, we discuss such an immunomodulatory activity, with a specific focus on molecular and cellular pathways that can be harnessed to develop superior combinatorial regimens for clinical EOC care.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30102 - Immunology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Trends in Cancer
ISSN
2405-8025
e-ISSN
2405-8025
Volume of the periodical
8
Issue of the periodical within the volume
5
Country of publishing house
US - UNITED STATES
Number of pages
19
Pages from-to
426-444
UT code for WoS article
000808335400010
EID of the result in the Scopus database
2-s2.0-85124669793